Pulmozyme recombinant human DNase enzyme to dissolve DNA in lung secretions data

The South San Francisco company reported results of a 244-patient Phase II trial showing significant decreases in mortality rates for treated patients (17 deaths with placebo vs. 7 deaths in the treatment group, p=0.02), and incidence of rehospitalization and of relapses (p=0.012 and 0.026 respectively), all during a 42-day follow-up period.

Extended follow-up over four months also found a decrease in mortality (p=0.002). However, the primary endpoints of the study did not reach statistical significance, including length of hospital stay, and spirometry readings for measuring lung function. ...